Pembrolizumab plus enfortumab vedotin for rare kidney cancers
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs—pembrolizumab (an immunotherapy) and enfortumab vedotin (a targeted therapy)—for people with collecting duct carcinoma or renal medullary carcinoma, two rare types of kidney cancer that have spread. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older.
- You must have been diagnosed with collecting duct carcinoma or renal medullary carcinoma that has spread or cannot be removed with surgery.
- You must have a tumor sample (from a past biopsy or a new one) available for testing.
- You must be able to take care of yourself (ECOG score of 0 or 1).
- You must not have had prior treatment with any immunotherapy or targeted therapy like the study drugs.
- You must not have active brain tumors or certain autoimmune conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of immunotherapy and a targeted drug (axitinib) for people with advanced collecting duct carcinoma, a rare type of kidney cancer. The goal is to see if this treatment can shrink tumors or slow the cancer's growth.
This trial tests a two-drug combination (pembrolizumab and enfortumab vedotin) followed by maintenance pembrolizumab for people with advanced bladder cancer that has not been treated before. The goal is to see if this approach helps control the cancer for longer.
This trial tests a combination of two drugs (enfortumab vedotin and pembrolizumab) for people with certain rare cancers of the urinary tract or testicles. The goal is to see if these treatments can shrink tumors or stop them from growing.
This trial studies enfortumab vedotin plus pembrolizumab (immunotherapy) for people with advanced bladder cancer that has a “variant” or non-urothelial subtype. It aims to shrink tumors and improve outcomes when standard options have not worked or are no longer enough.
This Phase 2 study tests giving pembrolizumab (an immune therapy) and enfortumab vedotin (an antibody-drug medicine) before and after surgery to remove high-risk upper urinary tract cancer. The goal is to lower the chance the cancer comes back.
This trial tests a combination of two drugs, enfortumab vedotin and pembrolizumab, to treat bladder cancer that has grown into the muscle of the bladder. The goal is to shrink or eliminate the cancer so that surgery to remove the bladder may not be needed.
Hear when a new Collecting Duct Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.